Discovery on Target
Discovery on Target Mobile Header


2015 Media Gallery


Next Event to Take Place September 19-22, 2016 in Boston

Discovery on Target would like to thank all of the speakers and attendees, sponsors and exhibitors who came to Boston for this year’s annual event. The event drew a large number of attendees with 1,100+ participants from 26 countries networking and discussing current and emerging ‘hot’ drug targets for the pharmaceutical industry.

Highlights of this year’s Discovery on Target include:

  • -300+ speakers presenting 200+ scientific presentations across 15 conference tracks and 13 short courses

New Programs:

  • Targeting the Microbiome
  • Gene Therapy Breakthroughs
  • Targeting the Unfolded Protein Response
  • Quantitative Systems Pharmacology

-New Symposia

  • Strategies for Rare Diseases
  • Developing CRISPR-based Therapies

-35+ interactive breakout discussion groups providing more opportunities to network, exchange ideas, and meet potential collaborators.

-Exhibit hall of 40+ companies with novel technologies and solutions

-100+ posters featuring cutting edge research from current and up-and-coming scientists and industry professionals

-Poster Program Winners

Deborah Dodge

Florence F. Wagner
#A22 Ensemble Therapeutics Corporation - Sethu Alexander; Julian Bond; Yan Chang; William Connors; Jeremy Duvall; Frank Favaloro; Stephen Hale; Revonda Mehovic; Kelley Shortsleeves; Nathan Walsh; Daniel Wang; Richard Martinelli; and Deborah Dodge: Inhibitors of USP9x Identified by High Throughput Selections of DNA Encoded Libraries

# B7 Broad Institute of MIT and Harvard - Arthur J. Campbell; Jennifer Gale; Deepika Walpita; Michael C. Lewis; Michel Weїwer; Joshua Sacher; Arnold Heynen; Laura Stoppel; Matt Robers; Michelle Walk; Shannon Nguyen; Doug Barker; Frank An; Michelle Palmer; Stephen J. Haggarty; Marc Bear; Edward Scolnick; Yan-Ling Zhang; Jen Q. Pan; Edward B. Holson; and Florence F. Wagner: Rational Design of Exquisitely Selective Inhibitors of the GSK3 Kinase Isoforms for the Treatment of Psychiatric and Neurological Disorders

-Student Fellowship Program offered to full time graduate students and Ph.D. candidates

-Plenary Keynote Program focused on the fundamental challenge for getting drugs to market sooner and cheaper is how best to judge and predict the success of drug candidates as efficiently and accurately as possible. Two speakers discussed cutting edge approaches for tackling this problem.

Plenary Keynote Speakers:

iPS Cell Technology, Gene Editing and Disease Research

Rudolf Jaenisch, M.D., Founding Member, Whitehead Institute for Biomedical Research; Professor, Department of Biology, Massachusetts Institute of Technology

The Evolutionary Dynamics and Treatment of Cancer

Martin Nowak, Ph.D., M.Sc., Professor, Biology and Mathematics and Director, Program for Evolutionary Dynamics, Harvard University

Plenary Keynote Introduction:

Comprehensive Kinase and Epigenetic Compound Profiling

Kelvin Lam, Ph.D., Director, Strategic Partnerships, Reaction Biology Corporation

Check out the Event’s official Twitter page for more highlights - #BostonDOT15

Save the date!
Next year’s Discovery on Target will be held September 19-22, 2016 in Boston

Missed the event?
Order the event proceedings. Although, we can’t make up for the networking and face-to-face discussions, we do offer conference proceedings on DVD. Order the entire event proceedings now available on DVD! Click here to place your order.

Interested in speaking, sponsoring, or exhibiting in 2016?

We will soon begin working on the program agenda for 2016. If you are interested in speaking, please contact Cindy Crowninshield, RDN, LDN, Senior Conference Director/Team Lead, at

To secure a sponsorship or exhibit package for 2016, contact Jon Stroup, Senior Business Development Manager at

2015 Photos


2015 Videos



Hear what your peers and colleagues said about this year’s event:

The Targeting the Microbiome Track was a very well organized meeting. Talks were very good, even the company sponsored ones.
Senior Partner at TranScrip Partners, GST Micro LLC

I wanted to thank you for inviting me to Discovery on Target. The meeting was terrific. I hadn’t realized what the breadth of the content would be, and am looking forward to taking in more of it next time!
Postdoc, Laboratory of Assay Development & Screening Technology, National Center for Advancing Translational Sciences, NIH  

It was a pleasure attending the conference and I was really pleased to see the industrial partners discussing the real science behind high throughout screenings in an open forum. Helps us to learn a lot and optimize our technology with current advancements in the field.
Scientist, German Cancer Research Center

I have to thank you for the chance to be part of this event. I think CHI’s conferences have become part of the “ecosystem” around drug discovery. Hopefully I will have a chance to stay involved and see you again in the future.
Director, Discovery and Chemical Biology, Lundbeck Research (chair)

This is one of the top GPCR meetings in the field. The speaker quality is excellent. Someone told me he only goes to two GPCR meetings – Keystone’s (or Gordon’s; whichever of the two is happening that year) and CHI’s. I think pharma comes to this meeting to hear the top guys in academia but there is an added plus of also being able to network w/ colleagues and listen to more applied talks than one would hear at society meetings
Director, Cell-based Screening Technologies, Bristol Myers-Squibb

You had a good selection of topics and speakers. I enjoyed the conference. The speakers were great…and with good science in the presentations.
Principal Scientist, Metabolic Disorders, Amgen  

This meeting is a good place to learn new things and network. My only regret is that I had not been attending this on a more regular basis. You folks have been doing this for a bit and seem to have ironed out all the kinks.
Professor, Pharmacology and Neuroscience, University North Texas Health Science Center

As always thank you for organizing this fantastic CHI conference! I learned a lot from my sessions. Can you invent a way that would allow me to attend ALL CHI sessions at the same time!
Assistant Professor, Northwestern University

I heard MANY people comment about what good speakers there were for the GPCR sections this year.
Assistant Professor, Pharmaceutical Sciences, Midwestern University  

Thank you again for the wonderful meeting, it really rocked this time! Would be great if GPCR track find its way to San Diego too, let us know how we can help it.
Assistant Professor, The Bridge Institute and Department of Biological Sciences, University of Southern California  

What I loved about the conference were the high-end speakers. I especially liked being able to be at a breakout session with Roderick Beijersbergen who is amazing – that was my star-struck moment on the Gene Therapy track. The speakers were excellent; I heard a lot of high powered science. I learned a lot and gained many different ideas on how to approach my research. It’s harder to get close to the ‘experts’ in bigger society meetings – this was close-knit -- Roderick Beijersbergen right at my table – amazing!
Graduate Student, Rice University  

I’m a fifth year graduate student in the MD/Ph.D. program at Penn. And being at this event stands out as a highlight of my past five years. I’d say being here was as exciting as passing my prelims. I’m so happy to have found a community where science and hard-core applications to drug discovery is the main focus – it’s exactly the area where I want to be working in and how I’m trying to focus my graduate work. I want to come to as many of your events as possible.
Krishna Vijayendran, MSTP Student, University of Pennsylvannia

We found Discovery on Target to be a great event, from the conference program of thought leaders to meeting valuable contacts inside the exhibit hall.
Marketing Consultant, Diversigen, Inc.

I thought the conference was a very convenient way to get better educated on the cutting edge R&D targeting the microbiome.
President & CEO, C3 Jian, Inc.

The organizers for Discovery on Target were easy to work with and very helpful. The conference was set-up well, and we had great conversations with people from all the disciplines represented.
Marketing Manager, LifeSensors, Inc.

The Discovery on Target conference has been a great source of leads for us across academic and pharma accounts. In addition, we have also developed collaborative relationships from our participation in Discovery on Target.
VP Marketing & Commercialization, Diagenode

As an antibody discovery company that focuses on difficult targets, we have found the Discovery on Target meeting to provide illuminating talks as well as one of the richest pools of potential collaborators that we have encountered at any conference.
Chief Science Officer & Co-Founder, Crystal Bioscience

Discovery on Target provided us with ample opportunity for invaluable face time with existing and potential customers.
Principal Scientist, Simulations Plus, Inc.

As a non-profit research institute with a mission to translate basic biomedical research into cutting-edge therapeutics, engaging partners and establishing the right collaborations are critical to our overall success. The Discovery on Target conference provided us the opportunity to engage high-level executives and scientists from the organizations – pharma, biotech, and academic alike – that we hope to target. You certainly lived up to your name!
Associate Director, Outreach, Alliances & Partnerships, Sanford Burnham Prebys Medical Discovery Institute

Discovery on target has been a great opportunity to meet with others within the community who are eager to experience new technologies and methods to answer functionally challenging questions related to both new and old biology. Discovery on Target has provided us with a great opportunity to meet with new perspective clients, collaborators, and partners.
Senior Business Development Manager, Avacta Life Sciences

This meeting continues to be a welcome forum for cooperative exchange of ideas between academic, industry and tool providers. The camaraderie is refreshing!
Senior Product Manager, Dharmacon, part of GE Healthcare

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Register Today!

Final Agenda Now Available









The exhibit hall was sold out in 2015, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2016, contact:

Jon Stroup
Sr. Business Development Manager






Next-Generation Histone Deacetylase Inhibitors

Strategies for Tackling Rare Genetic Diseases

Understanding CRISPR: Mechanisms and Applications

Autoimmunity – Small Molecule Approaches

NK Cell-Based Cancer Immunotherapy

Medical Dermatology Therapeutic R&D and Technical Innovation



Targeting Histone Methyltransferases and Demethylases

Targeting the Ubiquitin Proteasome System

Targeting the Microbiome
– Part 1

GPCR-Based Drug Discovery - Part 1

Advances in Gene Editing and Gene Silencing – Part 1

Gene Therapy Breakthroughs

Antibodies Against Membrane Protein Targets – Part 1

Targeting Cardio-Metabolic Diseases

Targeting Ocular Disorders


Targeting Epigenetic Readers and Chromatin Remodelers

Kinase Inhibitor Discovery

Targeting the Microbiome
– Part 2

GPCR-Based Drug Discovery - Part 2

Advances in Gene Editing and Gene Silencing – Part 2

Translating Cancer Genomics

Antibodies Against Membrane Protein Targets – Part 2

Metabolomics in Drug Discovery

TRAINING SEMINAR: Data Visualization


Monday, September 19
8:00 - 11:00 am

(SC1) Immunology Basics for Chemists

(SC2) Designing Peptide Therapeutics for Specific PPIs

(SC3) Phenotypic Screening and Chemical Probe Development

(SC4) Medical Dermatology Therapeutic R&D and Technical Innovation - Part 1

Monday, September 19
2:00 - 3:00 pm

(SC5) GPCR Structure-Based Drug Discovery

(SC6) RNA as a Small Molecule Drug Target

(SC7) Using IP Landscape Studies to Improve Your Confidence

(SC8) Medical Dermatology Therapeutic R&D and Technical Innovation - Part 2

Monday, September 19
3:30 - 6:30 pm

(SC9) Targeting of GPCRs with Monoclonal Antibodies

(SC10) Introduction to Targeted Covalent Inhibitors

(SC11) Contact Lens Drug Delivery Systems

(SC12) Introduction to Gene Editing

Monday, September 19
7:00 - 9:30 pm

(SC13) Convergence of Immunotherapy and Epigenetics for Cancer Treatment

Wednesday, September 21
7:00 - 9:30 pm

(SC14) Cancer Metabolism: Pathways, Targets and Clinical Updates

(SC15) Introduction to Allosteric Modulators and Biased Ligands of GPCRs

(SC16) Functional Screening Strategies Using CRISPR and RNAi

(SC17) Challenges and Opportunities in DNA Methyl Transferase (DNMT) Inhibitors as Therapeutics